Search
Hollywood, FL Paid Clinical Trials
A listing of 192 clinical trials in Hollywood, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 192
There are currently 192 clinical trials in Hollywood, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Memorial Regional Hospital/Joe DiMaggio Children's Hospital, GSK Investigational Site, Memorial Healthcare System and Memorial Cancer Institute at Memorial Regional Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS .
Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 o... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/21/2025
Locations: Skin Care Research - Hollywood /ID# 263805, Hollywood, Florida
Conditions: Hidradenitis Suppurativa
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/21/2025
Locations: Encore Medical Research /ID# 245682, Hollywood, Florida
Conditions: Migraine
Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease
Recruiting
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Gender:
ALL
Ages:
Between 18 years and 67 years
Trial Updated:
07/20/2025
Locations: Foundation for Sickle Cell Disease Research, LLC, Hollywood, Florida
Conditions: Proteinuric Kidney Disease
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
Recruiting
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
07/19/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Recurrent Low Grade Astrocytoma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Recurrent WHO Grade 2 Glioma, Refractory WHO Grade 1 Glioma
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Recruiting
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Millennium Oncology Research Clinic, Hollywood, Florida
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/18/2025
Locations: Research Site, Hollywood, Florida
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Recruiting
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).
For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/18/2025
Locations: Research Centers of America ( Hollywood ), Hollywood, Florida
Conditions: Alcohol Use Disorder
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
07/17/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
07/17/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
07/17/2025
Locations: South Florida Rheumatology /ID# 268525, Hollywood, Florida
Conditions: Systemic Lupus Erythematosus
1 - 12 of 192